Fig. 5.

Intravenous administration of PF-05082566 to cynomolgus monkeys induces proliferation of CD8+ memory T cells. a, b Multiple dose administration. Cynomolgus monkeys were injected intravenously with the indicated doses of PF-05082566 on days 1 and 8 of the study (n = 10 animals per group). On day 13, blood was collected, and cells were analyzed by flow cytometry. a The far left plot shows the gating strategy for identifying CD8+ T_CM (CD95+ CD28+) and CD8+ T_EM (CD95+ CD28−). The remainder of the plots shows representative staining for Ki-67 versus CD28 for CD8+ T_CM (top row) and CD8+ T_EM (bottom row) at the indicated dose levels. b Multiple dose administration of the indicated dose levels of PF-05082566 on day 1 and day 8 demonstrates significant increases in Ki-67+ CD8+ T_CM cells (graph on left) and Ki-67+ CD8+ T_EM (graph on right) as measured on study day 13. c Single dose administration of 0.05 mg/kg (white bars), 1 mg/kg (gray bars), or 10 mg/kg (black bars) PF-05082566 to 2 individual animals per group demonstrates increases in Ki-67+ CD8+ T_CM cells measured by FACS on study days 7 and 23 post dosing. For both b and c, fold changes were calculated relative to baseline pre-study samples collected prior to the start of dosing. Statistical significance was calculated using 1-way ANOVA with Dunnett’s Multiple Comparison test (*p < 0.05, ***p < 0.001)